AACR19: MET inhibitor savolitinib shows promise for EGFR-mutant NSCLC

Written by Martha Powell, Future Science Group

The addition of the investigational MET inhibitor savolitinib to the EGFR inhibitor osimerinib (Tagrisso®) is beneficial for certain pre-treated patients with EGFR-mutant non-small-cell lung cancer (NSCLC), according to results from the TATTON trial presented at the AACR Annual Meeting (March 29 – April 3, Atlanta, GA, USA). “Data from the TATTON trial demonstrate for the first time the benefit of adding a MET inhibitor to an EGFR inhibitor in patients with EGFR-mutant NSCLC and with MET-driven acquired resistance.” The results presented are interim data from two expansion cohorts of the Phase Ib trial, TATTON, demonstrating that there could be better...

To view this content, please register now for access

It's completely free